Site Map

Polycythemia - newborn

Neonatal polycythemia; Hyperviscosity - newborn

Polycythemia can occur when there are too many red blood cells (RBCs) in an infant's blood.

Images

Blood cells

I Would Like to Learn About:

Causes

The percentage of RBCs in the infant's blood is called the "hematocrit." When this is greater than 65%, polycythemia is present.

Polycythemia can result from conditions that develop before birth. These may include:

The extra RBCs can slow or block the flow of blood in the smallest blood vessels. This is called hyperviscosity. This may lead to tissue death from lack of oxygen. This blocked blood flow can affect all organs, including the kidneys, lungs, and brain.

Symptoms

Symptoms may include:

Exams and Tests

There may be signs of breathing problems, kidney failure, low blood sugar, or newborn jaundice.

If the baby has symptoms of hyperviscosity, a blood test to count the number of RBCs will be done. This test is called a hematocrit.

Other tests may include:

Treatment

The baby will be monitored for complications of hyperviscosity. Fluids may be given through the vein. A partial volume exchange transfusion is sometimes still done in some cases. However, there is little evidence that this is effective. It is most important to treat the underlying cause of the polycythemia.

Outlook (Prognosis)

The outlook is good for infants with mild hyperviscosity. Good results are also possible in infants who receive treatment for severe hyperviscosity. The outlook will depend largely on the reason for the condition.

Some children may have mild developmental changes. Parents should contact their health care provider if they think their child shows signs of delayed development.

Possible Complications

Complications may include:

Related Information

Fine motor control

References

Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM. Blood disorders. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 124.

Letterio J, Pateva I, Petrosiute A, Ahuja S. Hematologic and oncologic problems in the fetus and neonate. In: Martin RJ, Fanaroff AA, Walsh MC, eds. Fanaroff and Martin's Neonatal-Perinatal Medicine. 11th ed. Philadelphia, PA: Elsevier; 2020:chap 79.

Tashi T, Prchal JT. Polycythemia. In: Lanzkowsky P, Lipton JM, Fish JD, eds. Lanzkowsky's Manual of Pediatric Hematology and Oncology. 6th ed. Cambridge, MA: Elsevier Academic Press; 2016:chap 12.

BACK TO TOP

Review Date: 4/4/2019  

Reviewed By: Liora C. Adler, MD, Pediatric Emergency Medicine, Joe DiMaggio Children's Hospital, Hollywood, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2020 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.